title: RhG-CSF improves radiation-induced myelosuppression and survival in the canine exposed to fission neutron irradiation.
abstract: Fission-neutron radiation damage is hard to treat due to its critical injuries to hematopoietic and gastrointestinal systems, and so far few data are available on the therapeutic measures for neutron-radiation syndrome. This study was designed to test the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in dogs which had received 2.3 Gy mixed fission-neutron-γ irradiation with a high ratio of neutrons (~90%). Following irradiation, rhG-CSF treatment induced 100% survival versus 60% in controls. Only two of five rhG-CSF-treated dogs experienced leukopenia (white blood cells [WBC] count < 1.0 × 10(9)/L) and neutropenia (neutrophil [ANC] count < 0.5 × 10(9)/L), whereas all irradiated controls displayed a profound period of leukopenia and neutropenia. Furthermore, administration of rhG-CSF significantly delayed the onset of leukopenia and reduced the duration of leucopenia as compared with controls. In addition, individual dogs in the rhG-CSF-treated group exhibited evident differences in rhG-CSF responsiveness after neutron-irradiation. Finally, histopathological evaluation of the surviving dogs revealed that the incidence and severity of bone marrow, thymus and spleen damage decreased in rhG-CSF-treated dogs as compared with surviving controls. Thus, these results demonstrated that rhG-CSF administration enhanced recovery of myelopoiesis and survival after neutron-irradiation.
authors.affiliation: Department of Experimental Therapeutic of Radiation Sickness, Beijing Institute of Radiation Medicine, China.
authors.forename: Zu-Yin
authors.initials: ZY
authors.lastname: Yu
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: A-Ru-Na
authors.initials: AR
authors.lastname: Han
authors.forename: Shuang
authors.initials: S
authors.lastname: Xing
authors.forename: Hong-Ling
authors.initials: HL
authors.lastname: Ou
authors.forename: Guo-Lin
authors.initials: GL
authors.lastname: Xiong
authors.forename: Ling
authors.initials: L
authors.lastname: Xie
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Zhao
authors.forename: He
authors.initials: H
authors.lastname: Xiao
authors.forename: Ya-Jun
authors.initials: YJ
authors.lastname: Shan
authors.forename: Zhen-Hu
authors.initials: ZH
authors.lastname: Zhao
authors.forename: Xiao-Lan
authors.initials: XL
authors.lastname: Liu
authors.forename: Yu-Wen
authors.initials: YW
authors.lastname: Cong
authors.forename: Qing-Liang
authors.initials: QL
authors.lastname: Luo
mesh_terms: D000818:Animals; D002470:Cell Survival; D004285:Dogs; D005720:Gamma Rays; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism*; D006801:Humans; D007970:Leukopenia / Q000188:drug therapy / Q000532:radiotherapy; D022423:Myeloid Cells / Q000166:cytology; D009502:Neutrons; D009503:Neutropenia / Q000188:drug therapy / Q000532:radiotherapy; D009504:Neutrophils / Q000187:drug effects / Q000528:radiation effects; D011833:Radiation Injuries, Experimental / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000378:metabolism*; D014916:Whole-Body Irradiation
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor